Table 2 APS characteristics and outcomes in patients with and without non-criteria manifestations

Male sex, n (%)

14 (32.6)

53 (39.0)

0.564

Age, years, median [IQR]

53.00 [38.50, 69.50]

52.00 [39.00, 65.00]

0.758

 Thrombotic phenotype (pure), n (%)

26 (60.5)

86 (63.2)

0.884

 Obstetrical phenotype (pure), n (%)

6 (14.0)

22 (16.2)

0.913

 Combined APS, n (%)

11 ( 25.6)

29 ( 21.3)

0.708

 Number of thrombosis, n (%)

0.856

  None

7 (16.3)

24 (17.6)

  One

27 (62.8)

79 (58.1)

  Two or more

9 (20.9)

33 (24.3)

 Arterial thrombosis, n (%)

24 (55.8)

48 (35.3)

0.027

 Venous thrombosis, n (%)

17 (39.5)

73 (53.7)

0.149

 Miscarriages, n (%)

6 (14.3)

13 (9.9)

0.615

 Intrauterine deaths, n (%)

6 (14.3)

22 (16.8)

0.886

 Prematurity, n (%)

3 (7.1)

7 (5.3)

0.956

 IUGR, n (%)

3 (7.1)

7 (5.4)

0.965

 Pre-eclampsia, HELLP syndrome, n (%)

6 (14.3)

4 (3.1)

0.020

 CAPS, n (%)

2 (5.1)

0 (0.0)

0.074

 Arterial hypertension, n (%)

14 (51.9)

38 (38.4)

0.299

 Dyslipidemia, n (%)

8 (29.6)

23 (23.2)

0.666

 Tobacco, n (%) = 1 (%)

7 (35.0)

13 (21.3)

0.351

 Diabetes mellitus, n (%)

4 (19.0)

8 (12.5)

0.699

 Overweight, n (%)

5 (21.7)

25 (31.6)

0.511

 Anti-cardiolipid IgG, IU, median [IQR]

22.40 [5.00, 57.00]

18.00 [4.90, 63.00]

0.868

 Anti-cardiolipid IgG positive, n (%)

24 (57.1)

57 (49.6)

0.509

 Anti-cardiolipid IgM, IU, median [IQR]

11.00 [2.00, 53.35]

10.00 [2.20, 38.20]

0.980

 Anti-cardiolipid IgM positive, n (%)

17 (43.6)

46 (39.7)

0.807

 Anti-β2Gp1 IgG, IU, median [IQR]

17.10 [2.00, 60.00]

4.00 [1.00, 25.00]

0.312

 Anti-β2Gp1 IgG positive, n (%)

18 (42.9)

39 (33.6)

0.379

 Anti-β2Gp1 IgM, IU, median [IQR]

3.00 [1.00, 19.30]

3.00 [1.00, 29.45]

0.930

 Anti-β2Gp1 IgM positive, n (%)

13 (32.5)

36 (31.0)

1.000

 LAC, n (%)

19 (63.3)

51 (61.4)

1.000

 Triple positivity, n (%)

20 (47.6)

25 (19.8)

0.001

 Antinuclear antibodies, n (%)

15 (40.5)

22 (23.2)

0.075

 Vitamin K antagonists, n (%)

31 (77.5)

81 (64.8)

0.193

 Antiplatelet therapy, n (%)

19 (50.0)

58 (45.3)

0.746

 Hydroxychloroquine, n (%)

12 (31.6)

19 (14.7)

0.035

 Steroids, n (%)

12 (34.3)

18 (14.4)

0.016

 Relapse, n/total n (%)

20/34 (58.8)

33/98 (33.7)

0.018

 Death, n/total n (%)

5/37 (13.5)

5/103 (4.9)

0.167

 Time to relapse, years, median [IQR]

3.58 [1.23, 12.54]

1.71 [0.48, 5.77]

0.260

 Follow-up, years, median [IQR]

5.37 [0.96, 11.98]

2.95 [1.09, 7.83]

0.191